This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics
by Zacks Equity Research
CPRX, ZVRA, TBPH, ALDX, and LRMR shine amid tariff threats, thanks to strong pipelines, demand, and rising earnings estimates.
5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats
by Kinjel Shah
Innovation is at its peak in the Zacks Medical-Drugs industry. CPRX, ZVRA, TBPH, ALDX and LRMR may prove to be good additions to one's portfolio.
SLDB Stock Up as FDA Clears IND for SGT-212 in Friedreich's Ataxia
by Zacks Equity Research
Solid Biosciences rises as the FDA clears SGT-212, a gene therapy candidate, for clinical studies for the treatment of Friedreich's ataxia.
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance
by Zacks Equity Research
Madrigal, Corcept, Catalyst Larimar and Theravance have been highlighted in this Industry Outlook article.
5 Small Drug Stocks to Buy as Trump Gets Re-Elected
by Kinjel Shah
Innovation is at its peak for the Zacks Medical-Drugs industry. MDGL, CORT, CPRX, LRMR and TBPH may prove to be good additions to one's portfolio.
Wall Street Analysts Think Larimar (LRMR) Could Surge 192.89%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Larimar (LRMR) points to a 192.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
The Zacks Analyst Blog Highlights Biogen, Ionis Pharmaceuticals, GSK, PTC Therapeutics and Larimar Therapeutics
by Zacks Equity Research
Biogen, Ionis Pharmaceuticals, GSK, PTC Therapeutics and Larimar Therapeutics are part of the Zacks top Analyst Blog.
Biotech Stock Roundup: BIIB's Acquisition, PTCT, LRMR Gain on Updates & More News
by Zacks Equity Research
Biogen (BIIB) and PTC Therapeutics, Inc. (PTCT) are in the spotlight following acquisition news and regulatory updates, respectively.
Larimar (LRMR) Up on Lifting of Partial Clinical Hold on FA Study
by Zacks Equity Research
The FDA removes the partial clinical hold on Larimar's (LRMR) nomlabofusp clinical program for the treatment of patients with Friedreich's Ataxia.
Nektar Therapeutics (NKTR) Q1 Earnings & Revenues Beat
by Zacks Equity Research
Nektar's (NKTR) Q1 loss is narrower than expected while revenues beat estimates.
Larimar (LRMR) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Larimar (LRMR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Theravance's (TBPH) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Thervance's (TBPH) first-quarter 2023 loss wider than expected. Revenues decline year over year and also miss estimates.
New Strong Buy Stocks for May 9th
by Zacks Equity Research
SBGI, AQST, PLTK, GTX and LRMR have been added to the Zacks Rank #1 (Strong Buy) List on May 9, 2023
United Therapeutics (UTHR) Q1 Earnings Beat, Sales Miss
by Zacks Equity Research
United Therapeutics' (UTHR) first-quarter 2023 earnings beat estimates while sales miss the same. Tyvaso sales continue to drive the company's top line.
Best Momentum Stocks to Buy for April 19th
by Zacks Equity Research
LRMR, VRTV and PLL made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 19, 2023.
New Strong Buy Stocks for April 19th
by Zacks Equity Research
SIGA, RYI, LRMR, VRTV and PLL have been added to the Zacks Rank #1 (Strong Buy) List on April 19, 2023.
Here's Why You May Add Nektar (NKTR) Stock to Your Portfolio
by Zacks Equity Research
Here we discuss some reasons why investing in Nektar Therapeutics (NKTR) stock now is a good idea despite its several pipeline setbacks.
Here's Why You Should Invest in Larimar (LRMR) Stock Now
by Zacks Equity Research
Here we discuss some reasons why investing in Larimar Therapeutics (LRMR) stock now is a good idea.
Here's Why You Can Add KalVista (KALV) Stock to Your Portfolio
by Zacks Equity Research
Here we discuss some reasons why investing in KalVista Pharmaceuticals (KALV) stock now is a good idea.
New Strong Buy Stocks for April 12th
by Zacks Equity Research
CELU, MGI, LRMR, EQRX and SRZN have been added to the Zacks Rank #1 (Strong Buy) List on April 12, 2023.
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, KalVista Pharmaceuticals, Larimar Therapeutics, Nektar Therapeutics and Jounce Therapeutics
by Zacks Equity Research
Catalyst Pharmaceuticals, KalVista Pharmaceuticals, Larimar Therapeutics, Nektar Therapeutics and Jounce Therapeutics are part of the Zacks Industry Outlook article.
5 Stocks to Buy as the Drug Industry Rebounds in 2023
by Kinjel Shah
Innovation is expected to continue driving growth in the Medical-Drugs industry in 2023. CPRX, KALV, LRMR, NKTR, JNCE may prove to be good additions to one's portfolio.
Down -24.74% in 4 Weeks, Here's Why You Should You Buy the Dip in Larimar (LRMR)
by Zacks Equity Research
Larimar (LRMR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Down -29.33% in 4 Weeks, Here's Why You Should You Buy the Dip in Larimar (LRMR)
by Zacks Equity Research
Larimar (LRMR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Down -30% in 4 Weeks, Here's Why You Should You Buy the Dip in Larimar (LRMR)
by Zacks Equity Research
Larimar (LRMR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.